cefprozil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	556	92665-29-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefprozil cefprozile cephprozyl cefprozil hydrate	Molecular weight: 389.43 Formula: C18H19N3O5S CLOGP: -1.87 LIPINSKI: 0 HAC: 8 HDO: 4 TPSA: 132.96 ALOGS: -3.42 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cefprozil
cefprozile
cephprozyl
cefprozil hydrate

Molecular weight: 389.43
Formula: C18H19N3O5S
CLOGP: -1.87
LIPINSKI: 0
HAC: 8
HDO: 4
TPSA: 132.96
ALOGS: -3.42
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1	g	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	90 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
EoM (Fraction excreted unchanged in urine)	73 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	42.88 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
CL (Clearance)	2.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.20 hours	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.59 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.21 L/kg	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.06 mg/mL	Benet LZ, Broccatelli F, Oprea TI

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Dec. 23, 1991	FDA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	79.47	30.63	52	897	310635	63177438
Tubulointerstitial nephritis and uveitis syndrome	31.11	30.63	5	944	240	63487833
Idiopathic urticaria	30.78	30.63	5	944	257	63487816

Showing 1 to 3 of 3 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	86.44	27.35	57	1310	298859	79444162
Urticaria	32.04	27.35	26	1341	185175	79557846
Idiopathic urticaria	31.80	27.35	5	1362	181	79742840
Tubulointerstitial nephritis and uveitis syndrome	28.86	27.35	5	1362	330	79742691

Showing 1 to 4 of 4 entries

Previous1Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	J01DC10	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Second-generation cephalosporins
CHEBI has role	CHEBI:36047	antibacterial drugs
FDA CS	M0003827	Cephalosporins
FDA EPC	N0000175488	Cephalosporin Antibacterial

Showing 1 to 4 of 4 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Acute otitis media	indication	3110003
Haemophilus Influenzae Acute Otitis Media	indication	19021002
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Bronchitis	indication	32398004	DOID:6132
Streptococcal tonsillitis	indication	41582007
Upper respiratory infection	indication	54150009
Acute bacterial sinusitis	indication	75498004
Tonsillitis	indication	90176007	DOID:10456
Acute Moraxella catarrhalis bronchitis	indication	195722003
Acute bacterial bronchitis	indication	233598009

Showing 1 to 10 of 25 entries

Previous1 2 3Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.7	acidic
pKa2	9.72	acidic
pKa3	7.63	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
003623	NDDF
121123-17-9	SECONDARY_CAS_RN
12219	IUPHAR_LIGAND_ID
19552	RXNORM
387538005	SNOMEDCT_US
4020058	VUID
4020058	VANDF
4382	MMSL
4W0459ZA4V	UNII
5281006	PUBCHEM_CID

Showing 1 to 10 of 22 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cefprozil	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1077	TABLET, FILM COATED	250 mg	ORAL	ANDA	25 sections
Cefprozil	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1077	TABLET, FILM COATED	250 mg	ORAL	ANDA	25 sections
Cefprozil	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1078	TABLET, FILM COATED	500 mg	ORAL	ANDA	25 sections
Cefprozil	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1078	TABLET, FILM COATED	500 mg	ORAL	ANDA	25 sections
Cefprozil	Human Prescription Drug Label	1	16714-396	POWDER, FOR SUSPENSION	125 mg	ORAL	ANDA	25 sections
Cefprozil	Human Prescription Drug Label	1	16714-396	POWDER, FOR SUSPENSION	125 mg	ORAL	ANDA	25 sections
Cefprozil	Human Prescription Drug Label	1	16714-397	POWDER, FOR SUSPENSION	250 mg	ORAL	ANDA	25 sections
Cefprozil	Human Prescription Drug Label	1	16714-397	POWDER, FOR SUSPENSION	250 mg	ORAL	ANDA	25 sections
Cefprozil	Human Prescription Drug Label	1	16714-398	TABLET, FILM COATED	250 mg	ORAL	ANDA	25 sections
Cefprozil	Human Prescription Drug Label	1	16714-398	TABLET, FILM COATED	250 mg	ORAL	ANDA	25 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next